Mirum Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 264
- Market Cap
- $2.1B
- Website
- http://www.mirumpharma.com
- Introduction
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04168385
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇵🇱The Children's Memorial Health Institute, Warsaw, Poland
🇺🇸Children'S Hospital Los Angeles, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03905330
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hanover, Germany
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇫🇷Hospices Civils de Lyon - Hopital Femme Mere Enfant Service de Gastroenterologie, Hepatologie et Nutrition, Lyon, France
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
- Conditions
- Interventions
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Registration Number
- NCT03353454
The REPLACE Registry for Cholbam® (Cholic Acid)
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT03115086
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Kidz Pediatric Multispecialty Group, Hollywood, Florida, United States
🇺🇸Nemours duPont Pediatrics Specialty Clinic, Jacksonville, Florida, United States
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 197
- Registration Number
- NCT02787304
- Locations
- 🇺🇸
South Denver Gastroenterology, PC, Englewood, Colorado, United States
🇺🇸Internal Medicine Associates of Wellstar Atlanta Medical, Atlanta, Georgia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
- Conditions
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02571192
- Locations
- 🇺🇸
Covance Madison Clinical Research Unit, Madison, Wisconsin, United States
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
- Conditions
- Interventions
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT02475317
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Registration Number
- NCT02321306
- Locations
- 🇺🇸
Minnesota Gastroenterology, Saint Paul, Minnesota, United States
🇺🇸University of California at Davis, Sacramento, California, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT02287779
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02160782
- Locations
- 🇫🇷
Hopital Necker-Enfants Malades, Paris, France
🇬🇧Paediatric Liver Center, Kings College Hospital, London, United Kingdom
🇦🇺Children's Hospital Westmead, Westmead, New South Wales, Australia